Showing results (91-100 of 102) with videos related to
Sort By:
Pageof 11
Blood|July 20, 2011
Monoclonal antibody blockade of IL-2 receptor α during lymphopenia selectively depletes regulatory T cells in mice and humansDuane A Mitchell, Xiuyu Cui, Robert J Schmittling, et al.Neuro-Oncology|December 15, 2010
Greater chemotherapy-induced lymphopenia enhances tumor-specific immune responses that eliminate EGFRvIII-expressing tumor cells in patients with glioblastomaJohn H Sampson, Kenneth D Aldape, Gary E Archer, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 18, 2007
Partially matched, nonmyeloablative allogeneic transplantation: clinical outcomes and immune reconstitutionDavid A Rizzieri, Liang Piu Koh, Gwynn D Long, et al.Nature|March 13, 2015
Tetanus toxoid and CCL3 improve dendritic cell vaccines in mice and glioblastoma patientsDuane A Mitchell, Kristen A Batich, Michael D Gunn, et al.Neuro-Oncology|February 22, 2008
A pilot study: 131I-antitenascin monoclonal antibody 81c6 to deliver a 44-Gy resection cavity boostDavid A Reardon, Michael R Zalutsky, Gamal Akabani, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 10, 2006
Phase 1 trial of gefitinib plus sirolimus in adults with recurrent malignant gliomaDavid A Reardon, Jennifer A Quinn, James J Vredenburgh, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 31, 2005
Salvage radioimmunotherapy with murine iodine-131-labeled antitenascin monoclonal antibody 81C6 for patients with recurrent primary and metastatic malignant brain tumors: phase II study resultsDavid A Reardon, Gamal Akabani, R Edward Coleman, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 9, 2020
Rindopepimut with Bevacizumab for Patients with Relapsed EGFRvIII-Expressing Glioblastoma (ReACT): Results of a Double-Blind Randomized Phase II TrialDavid A Reardon, Annick Desjardins, James J Vredenburgh, et al.Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|June 3, 2006
Novel human IgG2b/murine chimeric antitenascin monoclonal antibody construct radiolabeled with 131I and administered into the surgically created resection cavity of patients with malignant glioma: phase I trial resultsDavid A Reardon, Jennifer A Quinn, Gamal Akabani, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 26, 2003
Phase II trial of gefitinib in recurrent glioblastomaJeremy N Rich, David A Reardon, Terry Peery, et al.Pageof 11